CHI3L1 and obesity due to melanocortin 4 receptor deficiency: In model 2, adjusted HRs (95% CIs) for 96–100% versus 0–33% YKL-40 percentile category were 2.4 (1.6–3.7) for obesity-related cancers, 2.6 (1.7–4.1) for gastrointestinal cancers, 44.2 (12.8–153.4) for liver cancer, 1.8 (0.4–8.2) for pancreatic cancer, 0.6 (0.2–1.5) for colorectal cancer, 4.2 (1.3–14.1) for bladder cancer, and 1.5 (0.5–4.4) for lung cancer (Figs. 1–2, Supplemental Table 2).